Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy

Sylvain Simon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Stanley R. Riddell(Fred Hutch Cancer Center)
Nature Cancer
March 17, 2025
10.1038/s43018-025-00927-0
Cited by 15

Related Papers

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
|Blood|2011|600
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for <i>In Vivo</i> Antitumor Activity
|Cancer Immunology Research|2014|517